3 ETFs That Hold AstraZeneca In Very Different Ways

LongbridgeAII'm LongbridgeAI, I can summarize articles.

You might like AstraZeneca for its cancer and rare disease research, but holding a single stock means living with its specific problems alone. Simply Wall St flags that AstraZeneca carries a high level of debt, and that setbacks like the failed Wainua heart disease trial can affect expectations for future medicines. Owning AstraZeneca inside a fund that also holds other healthcare and UK businesses limits how much those company specific swings can move your portfolio, and limits the upside to match.

The fresh news is that AstraZeneca has had a new cancer treatment, sonesitatug vedotin, accepted for Priority Review in the US for advanced stomach and related cancers, with a decision expected by the second quarter of 2027. That raises questions about what this could mean for its medicine line up and its role in funds like EWU, OZEM and JDOC if you prefer holding the stock through an ETF.

Rather choose individual stocks than a fund? Explore 35 high quality undervalued stocks.

iShares MSCI United Kingdom ETF (EWU)

Each US$1,000 in EWU puts about US$88 into AstraZeneca, so its high debt level still matters to your outcome. The rest of the ETF is spread across UK sectors, with sizeable stakes in diversified banks, integrated oil and gas, and aerospace and defense, plus exposure to areas like metals and mining, tobacco and personal care products. Large positions in HSBC Holdings and Shell together take up more of the fund than AstraZeneca, which keeps your overall mix tied to a broad slice of the UK market.

AstraZeneca’s high debt is tied to its own balance sheet and cannot be fixed by owning it through EWU alone. Other holdings in banks, energy groups and service firms face their own business cycles rather than AstraZeneca specific funding choices, which means EWU mixes your risk across several industries but still leaves questions about how the company’s leverage will affect its share price over time.

An ETF's price is just the sum of what it holds. Check whether EWU trades above or below its holdings' estimated cash flow value.

Roundhill GLP-1 & Weight Loss ETF (OZEM)

OZEM is heavily invested in companies tied to weight loss and related treatments, with pharmaceuticals at 75.8% of the portfolio and biotechnology at 21.5%. AstraZeneca takes up 3.22% of the ETF, so each US$1,000 puts about US$32 into the stock while most of your outcome is driven by other positions. Eli Lilly and Novo Nordisk together account for 31.2% of the fund, which makes this a concentrated way to back GLP-1 drug makers rather than a broad UK or global healthcare mix.

The failed Wainua cardiomyopathy trial shows how even late pipeline projects for AstraZeneca can still miss crucial clinical targets. OZEM spreads this kind of company specific risk across 24 holdings, including Eli Lilly and Novo Nordisk, whose results depend on their own obesity and diabetes franchises instead of AstraZeneca’s pipeline. You are still depending on a tight group of drug developers whose fortunes are closely linked to weight loss treatment trends and regulatory attitudes toward these therapies.

Compare how far OZEM is ahead of or behind the market across six periods

JPMorgan Healthcare Leaders ETF (JDOC)

UnitedHealth brings managed health care into JDOC, sitting alongside large holdings in Eli Lilly and AbbVie and a broad mix of pharmaceuticals, biotechnology and medical equipment groups. That blend means your money is spread across drug makers, healthcare distributors, life sciences tools and service businesses. AstraZeneca is the fund’s seventh largest line at 4.11%, so each US$1,000 in JDOC holds about US$41 of the stock while most outcomes lean on other healthcare holdings.

AstraZeneca still faces the risk that more late stage projects disappoint, which could narrow its future medicine range and strain long term revenue and earnings. JDOC only partly cushions that company specific risk, because its portfolio is concentrated in healthcare industries rather than spreading across banks, energy or other sectors. However, it still gives you a different industry split and a global mix that the single stock alone cannot offer.

Ten companies make up 49.2% of JDOC. Find out which ones, and how much each carries.

Choose what you want around AstraZeneca

In all three funds, AstraZeneca is important but not the whole story. Around US$88 out of every US$1,000 in EWU goes into the stock, compared with about US$41 in JDOC and US$32 in OZEM. EWU charges the lowest fee at US$50 a year on a US$10,000 holding and spreads your money across 75 positions that reach beyond healthcare into banks, oil and gas and other UK industries.

OZEM and JDOC both focus on health but in different ways. OZEM leans hard into weight loss drugs, while JDOC spreads across 61 medical businesses from insurers to equipment. Recent cancer drug news shows why pipeline progress matters for AstraZeneca. A key question for you is whether you want that exposure wrapped in a broad UK mix or tied mainly to healthcare trends.

With 20.3% of OZEM riding on Eli Lilly, its next few years matter as much as the fund's. See the earnings forecasts for Eli Lilly.

Fund data as of 13 November 2026. Portfolio holdings as of 13 November 2026.

Source: Simplywall The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.